AEON Biopharma, Inc.

AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
The Manila Times · 09 Oct 2026
AEON receives FDA feedback on ABP-450 biosimilar development path By Investing.com
Investing.com India · 30 Sep 2026
A 45-day expiry clock applies to AEON Biopharma (AEON) milestone warrants unless exercised.
Stock Titan · 30 Sep 2026
Aeon Biopharma, Inc. Receives Fda Type 2B Meeting Feedback Clarifying Biosimilar Development Plan for Abp-450
www.marketscreener.com · 30 Sep 2026
Aeon Biopharma Jumps 19% on FDA Feedback
Orange County Business Journal · 30 Sep 2026
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
The Manila Times · 30 Sep 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.